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In the absence of a vaccine or specific treatments for 
Ebola virus disease (EVD), early identification of cases 
is crucial for the control of EVD epidemics. We evalu-
ated a new extraction kit (SpeedXtract (SE), Qiagen) on 
sera and swabs in combination with an improved diag-
nostic reverse transcription recombinase polymerase 
amplification assay for the detection of Ebola virus 
(EBOV-RT-RPA). The performance of combined extrac-
tion and detection was best for swabs. Sensitivity 
and specificity of the combined SE and EBOV-RT-RPA 
were tested in a mobile laboratory consisting of a 
mobile glovebox and a Diagnostics-in-a-Suitcase pow-
ered by a battery and solar panel, deployed to Matoto 
Conakry, Guinea as part of the reinforced surveillance 
strategy in April 2015 to reach the goal of zero cases. 
The EBOV-RT-RPA was evaluated in comparison to two 
real-time PCR assays. Of 928 post-mortem swabs, 120 
tested positive, and the combined SE and EBOV-RT-
RPA yielded a sensitivity and specificity of 100% in ref-
erence to one real-time RT-PCR assay. Another widely 
used real-time RT-PCR was much less sensitive than 
expected. Results were provided very fast within 30 to 
60 min, and the field deployment of the mobile labora-
tory helped improve burial management and commu-
nity engagement.
Introduction
As of 11 October 2015, the ongoing Ebola virus disease 
(EVD) epidemic in West Africa has resulted in more 
than 28,500 cases and over 11,300 deaths. The early 
symptoms of EVD (i.e. fever, fatigue, headache, vomit-
ing and diarrhoea) are unspecific and present a chal-
lenge for clinical diagnosis [1]. In humans, death occurs 
generally seven to 10 days after the onset of symptoms. 
Survivors can be ill for up to 22 days before recovering 
[2]. Ebola virus (EBOV) infection is mainly diagnosed 
by various in-house and commercial real-time RT-PCR 
assays [3], used in up to 38 laboratories implemented 
at or close to Ebola treatment centres (ETC) in West 
Africa [4]. Transmission of EVD occurs almost exclu-
sively from human to human by direct contact with 
body fluids of symptomatic cases. Consequently, the 
control strategy for EVD epidemics relies on early iden-
tification of EBOV-infected patients and corpses for, 
respectively, isolation and safe burials. It is imperative 
to trace and follow up contacts and to implement infec-
tion control measures.
Therefore, rapid EVD diagnostics impact on outcome 
of treatment, efficiency of contact tracing and sub-
sequently community engagement, which is central 
to the successful control of the EVD epidemic. The 
World Health Organization (WHO) launched a call and 
consultation for an emergency procedure under its 
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pre-qualification programme for diagnostic tool assess-
ment [5] to support accelerated development, produc-
tion and deployment of adapted and rapid Ebola tests. 
Early in 2015, only three commercial real-time RT-PCR 
assays (RealStar Filovirus Screen, Altona Diagnostics, 
Hamburg, Germany; Liferiver Ebola Virus, Shanghai ZJ 
BioTech Co., Shanghai, China; GeneXpert Ebola virus, 
Cepheid, Solna, Sweden) and one rapid antigen detec-
tion test (ReEBOVTM (Corgenix, Denver, United States 
(US)) had been approved for emergency use, empha-
sising the need for such tests. At the time of publica-
tion of this article, nine real-time PCR assays for Ebola 
virus detection have been approved by the WHO.
In this study, we describe the optimisation, evalua-
tion of performance and operational characteristics 
of a real-time RT-PCR [6] and a rapid RT-recombinase 
polymerase amplification (RPA) [7] used for diagnosis 
of suspected Ebola cases, and compare them with the 
RealStar Filovirus Screen RT-PCR approved for emer-
gency use. In addition, we report the efficient field 
deployment of the rapid RT-RPA which boosted com-
munity engagement for safe and dignified burials.
Methods
Study design and samples
The study was conducted during the 2014–15 EBOV 
outbreak in Guinea. On 23 March 2014, the Institute 
Pasteur de Dakar (IPD), Senegal, upon request of the 
WHO and the Guinean Ministry of Health deployed 
a mobile laboratory team to Conakry. An ETC was 
set up at Donka hospital in Conakry. Serum samples 
from acute cases and swabs (cheek and tongue) from 
deceased meeting the WHO definition of a suspected 
EVD case (see below) were collected in Conakry, 
Matoto, Télimélé, Coyah and other regions of Guinea 
between December 2014 and May 2015 and sent to 
our laboratory for diagnosis. In addition, following an 
upsurge of EVD cases connected to funeral rites, oral 
swabs from all deceased were tested at the morgue 
in Matoto in March and April 2015. During this study, 
the EBOV RT-RPA was evaluated in parallel to reference 
methods.
Suspected EVD cases were defined as any person, 
alive or dead, suffering or having suffered from a sud-
den onset of high fever and having had contact with a 
suspected, probable or confirmed case of EVD, or any 
person with sudden onset of high fever and at least 
three of the following symptoms: headaches, anorexia/
loss of appetite, lethargy, aching muscles or joints, 
Figure 2
Mobile laboratory for Ebola virus diagnostics
A: Complete mobile laboratory including the solar power pack.
B: The Diagnostics-in-a-Suitcase (DiaS) contains all equipment and 
reagents to perform up to 100 RT-RPA assays
C: The workspace inside the glovebox contained a heat block 
mini (VWR International GmbH, Erlangen, Germany), a 96 box 
each of 100 µl and 1,000 µl sterile filter tips (BRAND, Wertheim, 
Germany), and two respective automatic micropipettes 
(Eppendorf AG, Hamburg, Germany), a waste container (Sarstedt, 
Nuembrecht, Germany), a magnetic separator stand (Promega, 
Madison, US), a rack for 1.5–2 ml tubes and a marker pen.
D: Transfer of the mobile laboratory (DiaS, aluminium box 
containing the glovebox and the PPE, solar panel and power 
pack).
E: Setup of the glovebox and the DiaS at a hospital in Matoto.
F: Ebola RT-RPA assay in the DiaS.
Figure 3
Assembly of the Diagnostics-in-a-Suitcase
A: A PVC layer was placed on top of the foam filling the bottom of 
the suitcase.
B: Bespoke insert slots were cut out of the PVC and the foam layer 
to host the tubescanner, the box for the disinfection wipes, the 
waste container, the vortex, the minicentrifuge and two boxes of 
refill pipette tips.
C: Foam, PVC layer and instruments were assembled outside the 
suitcase. Electricity wires were stowed underneath the foam 
layer. The equipment was fixed to the PVC layer using hot glue.
D: The setup was placed into the suitcase and the seams were 
sealed with hot glue.
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breathing difficulties, and any person with inexplicable 
bleeding or any sudden inexplicable death.
RNA extraction and inactivation
Two extraction methods were used. In the first method, 
viral RNA was extracted from 100 µl serum or swab 
transport medium using the QIAamp Viral Mini Kit 
(QC; Qiagen, Hilden, Germany). RNA was eluted in 50 
μl Tris-EDTA buffer. The second extraction protocol 
(SpeedXtract Nucleic Acid Kit (SE), Qiagen, Hilden, 
Germany) was a reverse extraction method extract-
ing protein debris by way of magnetic beads after an 
initial 10 min heating step at 95 °C. It yielded 200 µl 
supernatant from 20 µl of serum or oral swab transport 
fluid diluted 1:2 with molecular grade water. 
We added 5 µl of either eluate to the W-PCR (EBOV 
one-step real-time RT-PCR described in [6]) and the 
optimised RT-RPA, and 10 µl to the A-PCR (The RealStar 
Filovirus RT-PCR Kit, Altona-Diagnostics, Hamburg, 
Germany). 
To test for inactivation of EBOV by the new SE kit, SE 
extract dilutions from 10−1 to 10−5 were added in trip-
licate onto 2 × 105 VeroE6 cells in a 96-well plate and 
incubated for five days. The supernatant was passaged 
three times by transfer to a new well, followed by a 3 h 
incubation, a wash, and another 48 h incubation step. 
Finally, cells were washed three times and RNA was 
extracted in 200 µl Trizol and submitted to an EBOV in-
house PCR. For each dilution, three more wells to which 
the supernatants had been added in the same manner 
were subjected to an immunofluorescence assay after 
passage 1 [8]. A not extracted patient serum sample 
was used as positive control and showed virus growth 
on VeroE6 cells.
Real-time RT-PCR
The W-PCR was performed on the SmartCycler (Cepheid, 
Sunnyvale, US) using the RNA Master Hybridisation 
Probes kit (Roche, Manheim, Germany). A dried 10-fold 
primer and probe mix containing 100 pmol EBOZ FP and 
EBOZ RP and 50 pmol EBOZ P (TIB Molbiol, Germany) 
was used. The A-PCR was used on the SmartCycler 
according to the manufacturer`s instructions. Positive 
results above cycle threshold (Ct) 35 were regarded as 
equivocal and repeated for confirmation [9].
RT-RPA assay
The primers and the exo probe of an existing EBOV 
RT-RPA assay [7] were redesigned to adopt mismatches 
of the current EBOV outbreak strain (Figure 1, Table 1) 
following RPA design guidelines [10].
The RT-RPA was performed using a custom-made EBOV-
specific exo RT kit with pellets containing optimised 
enzyme concentrations similar to the commercial 
TwistAmp RT exo kit [10,11], and additionally contain-
ing primers and probe. Briefly, 5 µl of RNA template 
and 45 µl of customised rehydration buffer containing 
magnesium acetate were added to each pellet in a strip 
of eight tubes delivered in vacuum-sealed pouches. In 
each strip, tubes 1 to 5 were used to test samples, tube 
6 was used as negative extraction control and tubes 
7 and 8 for a negative and positive RT-RPA reaction 
control. The reaction tubes were mixed, centrifuged 
and then placed into the ESEQuant TS2 (QIAGEN Lake 
Constance GmbH, Stockach, Germany) for real-time 
monitoring of fluorescence at 42 °C for 15 min, with 
brief mixing and centrifugation of the reaction tubes 
after 4 min. The resulting curves were analysed by 
TS2 Studio Version 1.8.2.0 (QIAGEN Lake Constance 
GmbH, Stockach, Germany). Increase of fluorescence 
intensity over time above the mean background signal 
Figure 4
Sensitivity of the Ebola RT-recombinase polymerase 
amplification test on (A) inactivated Ebola virus and (B) 
swab samples, Guinea, December 2014–May 2015 (n=138)
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RPA: recombinase polymerase amplification; RT: reverse 
transcription; TT: threshold time.
A: Plasma samples spiked with inactivated Ebola virus (source: 
ENIVD) extracted and re-quantified by real-time PCR. Extracts 
(1.5 × 105, 7.0 × 102, 1.0 × 104, 1.0 × 105 Ebola genome 
molecules /reaction) were tested in triplicate by RT-RPA. The 
detection limit was 15 Ebola genome molecules/reaction in a 
maximum of 8 min.
B: Results from 138 swab samples from deceased suspected EVD 
cases with symptoms among a cohort of 928 samples from 
deceased with and without symptoms. Positive and negative 
results are scored over days after onset of disease.
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was analysed by threshold validation (mV/min). Slope 
validation was used to verify that the increase of fluo-
rescence occurred at a sufficiently high rate, and was 
verified by first derivative analysis.
The mobile laboratory
The mobile laboratory consisted of a glovebox (Bodo 
Koennecke, Berlin, Germany), a Diagnostics-in-a-
Suitcase (DiaS), and a solar panel and power pack 
set (Yeti 400 set, GOALZERO, South Bluffdale, US). 
The disassembled glovebox was kept in a metal box 
(80 × 60 × 41 cm) with other necessary materials (dis-
infectant solution, extraction kits, filter tips, racks, 
vortex, heat block, autoclavable plastic bags and per-
sonal protective equipment (PPE). The total weight 
was 28 kg for the box and 16 kg for the DiaS. Sample 
inactivation and RNA extraction using the SE kit were 
done in the glovebox (Figure 2A,B). This allowed han-
dling of hazard group 4 samples. The RT-RPA assay 
was performed in the DiaS (Figure 2A,C) containing 
the ESEQuant TS2 device with integrated touchscreen 
to operate the device and display the results (Qiagen, 
Lake Constance GmbH, Stockach, Germany). The DiaS 
was assembled using a trolley case (63 × 50 × 30.2 cm, 
Peli, Düsseldorf, Germany). The bottom layer of the 
DiaS contains foam to adsorb shocks during transpor-
tation which is covered by a PVC top layer fixed around 
inserted devices to provide water and chemical resist-
ance (Figure 3, [12]).
Statistical methods
Data were analysed using R (version 3.1.1) [13]. 
Performance parameters of the test (sensitivity (Se), 
specificity (Sp), positive (PPV) and negative predictive 
Name RPA primers and exo probes
EBOG RPA FP TGATCCRACTGACTCACAGGATACGACCATT*C 
EBOG RPA RP TCTAGATCGAATAGGAYCAARTCATCTGGTGC*A
EBOG RPA P GATGATGGARGCTACGGCGAATACCARAG-BTF-CTCGGAAAACGGYATG-Ph
Table 1
Primers and probe designed for the updated Zaire ebolavirus RT-recombinase polymerase amplification assay
B: thymidine nucleotide-carrying blackhole quencher 1; F: thymidine nucleotide-carrying fluorescein; FP: forward primer; P: probe; Ph: 3’ 
phosphate to block elongation; RP: reverse primer; T: tetrahydrofuran spacer. 
* phosphothioate backbone.
Table 2
Pathogen nucleic acids used for evaluation of the Ebola virus RT-recombinase polymerase amplification assay 
Pathogen Strain/source Ebola RT-RPA TT (min)
Real-time 
RT-PCR 
CT value
Real-time 
RT-PCR assay
Ebola virus Zaire strain/BNI 4.7 21.0
ENIVD Ebola standard control and [6]
Ebola virus GIN/2014/Gueckedou-C05/BNI 5 25.4
Sudan virus Sudan Virus Maridi Negative 22.26 [6]
Bundibugyo virus Bundibugyo virus Negative 28.7 In-house assay
Marburg virus Musoke/BNI Negative 24.5 [6]
Crimean Congo 
haemorrhagic fever virus
Kosova Hoti/BNI, 
Afg09–2990/BNI Negative
20.3 
22.4
RealStar CCHFV RT-PCR Kit ((Altona 
Diagnostics)
Lassa virus Josiah/BNI, Lib 1580/121/ BNI Negative
25.9, 
34.7 [16]
Yellow fever virus Asibi AY640589.1 17D RKI Negative
20.6, 
20.0 [17]
Rift valley fever virus Strain ZH548 Negative 26.2 [18]
Dengue virus 1–4
VR344 (Thai 1958 strain),  
VR345 (TH-36 strain), 
VR216 (H87 strain), 
VR217 (H241 strain)
Negative
24.2 
21.3 
23.1 
22.7
In-house assay
Zika virus MR766 Negative 20.86 [19]
Chikungunya virus A26 Strain Negative 25.13 In-house assay
Plasmodium falciparum ND Negative 15.0 In-house qualitative assay
BNI: Bernhard Nocht Institute; ND: not determined; GIN: Guinea; RKI: Robert Koch Institute; RPA: recombinase polymerase amplification; RT: 
reverse transcription; TT: threshold time. 
Ebola RT-RPA assay identified only Zaire ebolavirus but not the nucleic acids of other pathogens. 
6 www.eurosurveillance.org
values (NPV) were estimated for each of the assays 
using real-time RT-PCR assays as reference test. The 
95% confidence interval (CI) of performance param-
eters was calculated based on the exact binomial test. 
P values are derived from the exact binomial test. The 
calculated Se and Sp were considered statistically sig-
nificant for p values < 0.05. We used Fisher’s exact test 
to compare RT-RPA performance parameters in compar-
ison with W-PCR and A-PCR as the reference method at 
different Ct ranges.
Results
Inactivation
The inactivation of EBOV by the SE extraction proce-
dure was confirmed in VeroE6 cells inoculated with SE 
extracts which were all negative in IFA. PCR results at 
passage 4 ranged from Ct 32 to undetectable. Since the 
IFA was negative, the PCR results were assumed to be 
due to remnant input RNA but not to actively replicat-
ing virus.
Analytical sensitivity and specificity of the RT-
RPA assay
W-PCR and RT-RPA detected RNA standards over a 
range of 5 to 5 × 105 genome copies (GC)/reaction and 
50 to 5 × 105 genome copies/reaction, respectively. 
RT-RPA assays could detect as little as 5 GC/reaction 
of a molecular RNA standard (data not shown) and 15 
GC/reaction in EBOV-spiked human plasma samples 
(Figure 4A). No cross-detection of important differen-
tial diagnostic pathogens or any other filoviruses was 
observed for the Ebola RT-RPA assay (Table 2).
Performance of RT-PCR and RT-RPA assay 
using sera
Using a total of 141 sera extracted with QC, RT-RPA 
and W-PCR performances were assessed using the 
WHO-approved A-PCR as reference. Against the 
Table 3
Evaluation of Ebola virus diagnostic assays, serum and swab samples, Guinea, December 2014–May 2015 (n=1,069)
CI: confidence interval; CT: cycle threshold; NPV: negative predictive value; QC: QIAamp Viral Mini Kit; RPA: recombinase polymerase 
amplification; RT: reverse transcription; PPV: positive predictive value; SE: SpeedXtract nucleic acid extraction kit. 
a Extraction method for RT-RPA. In all cases the reference test was tested with extracts from QC. 
b Estimated proportions are given in decimals.
c This comparison was tested on a smaller subset.
Extraction 
method a
Sample 
type
Reference 
test
Analysed 
test Ct range
Analysis 
valuesb PPV NPV Sensitivity Specificity n
Analysed 
method
Reference method
Positive Negative
QC Serum 
A-PCR RT-RPA 0–40
Estimate: 
95% CI: 
p value:
0.82 
[0.72–0.9] 
3.2 × 10−9
0.97 
[0.88–1.00] 
1.19 × 10−14
0.97 
[0.90–1.00] 
4.21 × 10−18
0.79 
[0.60–0.88] 
1.04 × 10−6
141
Positive 68 15
Negative 2 56
A-PCR RT-RPA > 30
Estimate: 
95% CI: 
p value:
0.46 
[0.27–0.67] 
0.8450
0.97 
[0.88–1.00] 
1.19 × 10−14
0.86 
[0.57–0.98] 
0.0129
0.8 
[0.69–0.89] 
4.30 × 10−7
84
Positive 12 14
Negative 2 56
W-PCR RT-RPA 0–40
Estimate: 
95% CI: 
p value:
1 
[0.93–1.00] 
0.178
0.86 
[0.75–0.94] 
1.57 × 10−8
0.91 
[0.83–0.96] 
7.58 × 10−17
1 
[0.93–1.00] 
1.78 × 10−15
141
Positive 83 0
Negative 8 50
W-PCR RT-RPA > 30
Estimate: 
95% CI: 
p value:
1 
[0.87–1.00] 
2.98 × 10−8
0.86 
[0.75–0.94] 
1.57 × 10−8
0.76 
[0.59–0.89] 
0.0029
1 
[0.93–1.00] 
1.78 × 10−15
84
Positive 26 0
Negative 8 50
A-PCR W-PCR 0–40
Estimate: 
95% CI: 
p value:
0.77 
[0.67–0.85] 
2.51 × 10−7
1 
[0.93–1.00] 
1.78 × 10−15
1 
[0.95–1.00] 
1.69 × 10−21
0.7 
[0.58–0.81] 
0.0007
141
Positive 70 21
Negative 0 50
A-PCR W-PCR > 30
Estimate: 
95% CI: 
p value:
0.41 
[0.25–0.59] 
0.392
1 
[0.93–1.00] 
1.78 × 10−15
1 
[0.77–1.00] 
0.0001
0.71 
[0.59–0.82] 
0.0004
84
Positive 14 20
Negative 0 50
W-PCR A-PCR 0–40
Estimate: 
95% CI: 
p value:
1 
[0.95–1.00] 
1.69 × 10-21
0.7 
[0.58–0.81] 
7.67 × 10-4
0.77 
[0.67–0.85] 
2.51 × 10-7
1 
[0.93–1.00] 
1.78 × 10-15
141
Positive 70 0
Negative 21 50
W-PCR A-PCR > 30
Estimate: 
95% CI: 
p value:
1 
[0.77–1.00] 
0.0001
0.71 
[0.59–0.82] 
0.0004
0.41 
[0.25–0.59] 
0.3920
1 
[0.93–1.00] 
1.78 × 10−15
84
Positive 14 0
Negative 20 50
SE Swab 
A-PCR RT-RPA 0–40
Estimate: 
95% CI: 
p value:
0.81 
[0.71–0.89] 
1.39 × 10−8
1 
[1.00–1.00] 
1.20 × 10−240
1 
[0.95–1.00] 
1.36 × 10−20
0.98 
[0.97–0.99] 
2.86 × 10−212
881c
Positive 67 16
Negative 0 798
A-PCR RT-RPA > 30
Estimate: 
95% CI: 
p value:
0.5 
[0.31–0.69] 
1
1 
[1.00–1.00] 
1.20 × 10−240
1 
[0.78–1.00] 
6.10 × 10−5
0.98 
[0.97–0.99] 
1.12 × 10−213
828c
Positive 15 15
Negative 0 798
W-PCR RT-RPA 0–40
Estimate: 
95% CI: 
p value:
1 
[0.96–1.00] 
4.14 × 10−25
1 
[0.99–1.00] 
3.69 × 10−127
1 
[0.96–1.00] 
4.14 × 10−25
1 
[0.99–1.00] 
3.69 × 10−127
928
Positive 120 0
Negative 0 808
W-PCR RT-RPA > 30
Estimate: 
95% CI: 
p value:
1 
[0.88–1.00] 
3.73 × 10−9
1 
[0.99–1.00] 
3.69 × 10−127
1 
[0.88–1.00] 
3.73 × 10−9
1 
[0.99–1.00] 
3.69 × 10−127
863c
Positive 55 0
Negative 0 808
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A-PCR, the RT-RPA yielded a lower PPV (82% vs 100%, 
p = 3.05 × 10−5), a higher corresponding Se (97% vs 
91%, p = 0.19), a higher NPV (97% vs 86%, p = 0.09) and 
a lower Sp (79% vs 100%, p = 3.45 × 10−4) than against 
the W-PCR (Table 3 rows 1 and 3, Table 4). The tendency 
of the results was even more pronounced in the subset 
of 84 samples with low viraemia (Ct values > 30, Table 3 
rows 2 and 4). The difference between the PCR assays 
was analysed and revealed a reduced Se (77%) for the 
A-PCR compared with the W-PCR (Table 3 rows 7–8).
Samples determined as positive by the W-PCR but neg-
ative by the RT-RPA were also negative in the A-PCR, 
which missed some additional samples. There was no 
case of a negative RT-RPA result being positive in the 
A-PCR (Table 5).
Performance of RT-PCR and RT-RPA assay 
using swabs
In a preliminary test of RT-RPA efficiency on SE extracts 
from 47 swabs from deceased patients, all 47 samples 
scored positive in the W-PCR and the RT-RPA. Therefore, 
combined SE extraction and RT-RPA were deployed in 
the mobile laboratory and altogether 928 post-mortem 
swab samples (including the 47 preliminary ones) were 
tested. All 928 samples were also extracted by QC 
and tested by W-PCR and A-PCR. Overall, 120 samples 
scored positive both in W-PCR and RT-RPA, and only 67 
of a subset of 83 samples scored positive in A-PCR. In 
reference to QC extraction and W-PCR, SE extraction 
and RT-RPA yielded a Se and Sp of 100% each (PPV: 
100%; NPV: 100%). Since the results of W-PCR and 
RT-RPA were concordant, the significance of the results 
was not calculated (Table 5).
The prevalence of positives as tested by W-PCR and 
RT-RPA in the 928 swabs was 12.9%. Of the 928 post-
mortem samples tested, 790 were from suspected cases 
for whom no signs of disease were recorded and 138 
from suspected cases for whom information on symp-
toms and onset of disease ranging from 1 to 35 days 
before death were available. Of the 120 positive cases, 
53 belonged to the group without recorded symptoms 
and 67 belonged to the group with symptoms. Positive 
results were most frequent around day 6 after disease 
onset and no positive results were obtained later than 
14 days after onset of disease (Figure 4B).
Deployment of the mobile laboratory to the 
local hospital in Guinea
The mobile laboratory was easy to transport to the 
point of need (Figure 2D-F). The setup of the mobile 
laboratory including the assembly of the glovebox and 
donning the PPE took ca 30 min. The SE step was per-
formed in the glovebox for up to 10 samples in 30 min, 
while the RT-RPA needed 20 min including pipetting 
steps and mixing. We were able to power the mobile 
laboratory (peak energy need: 173 W) with the solar 
battery for up to 16 hours. Before moving to another 
spot, the glovebox and DiaS were disinfected with 2% 
bleach or 0.5% incidine. Altogether, setup, operation 
and disassembly of the unit was easy to perform in a 
timely manner.
Four Guinean biologists were equipped with and 
trained in the use of the mobile laboratory at the IPD in 
January 2015 in a five-day course. After a pilot phase in 
Guinea, the mobile laboratories were deployed in the 
Matoto district of Conakry to support testing of swabs 
from dead suspected cases, which was introduced to 
Table 4
Significance of the performance analysis results for Ebola 
virus diagnostic assays, serum samples, Guinea, December 
2014–May 2015 (n=141)
Ct range RPA/W-PCR RPA/A-PCR Fisher’s exact test p value 
Se All 0.91 0.97 0.19
Sp All 1 0.79 3.45 × 10−4
PPV All 1 0.82 3.05 × 10−5
NPV All 0.86 0.97 0.09
Se 0–20 1 1 1.00
Sp 0–20 1 1 1.00
PPV 0–20 1 1 1.00
NPV 0–20 1 1 1.00
Se 0–30 1 1 1.00
Sp 0–30 1 0.98 1.00
PPV 0–30 1 0.98 1.00
NPV 0–30 1 1 1.00
Se > 30 0.76 0.86 0.70
Sp > 30 1 0.80 3.27 × 10−4
PPV > 30 1 0.46 1.09 × 10−5
NPV > 30 0.86 0.97 0.09
NPV: negative predictive value; RPA: recombinase polymerase 
amplification; RT: reverse transcription; PPV: positive predictive 
value; Se: Sensitivity; Sp: Specificity.
Table 5
Concordance of results from Ebola virus diagnostic assays, 
serum and swab samples, Guinea, December 2014–May 
2015 (n=928)
Sera W-PCR RT-RPA A-PCR
Positive 91 83 70
Negative 50 58 71
Total 141 141 141
Swabs W-PCR RT-RPA A-PCR
Positive 83 83 67
Negative 798 798 814
Total 881 881 881
Forty-seven additional swab samples were only tested by W-PCR 
and RT-RPA. In n = 928 samples, these two assays were 
absolutely concordant.
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improve community engagement in the EBOV response 
as well as community surveillance.
Discussion
In this study, we evaluated the analytical and clinical 
performance of an updated EBOV RT-RPA compared 
with reference real-time RT-PCR assays. The isother-
mal RT-RPA assay, which allows real-time detection of 
amplification from RNA samples using primers and a 
fluorescent restriction probe within 3 to 15 min [10]. 
We improved this assay by adaptating the primers to 
the new sequences of the EBOV strain circulating in 
West Africa and incorporating them into dried RT-RPA 
pellets.
In sera extracted by QC, the RT-RPA scored a Se of 91% 
and Sp of 100% in reference to the W-PCR (Se: 97% 
and Sp: 79% in reference to the A-PCR), which means it 
would miss out some weak positives while identifying 
all true negatives correctly. Results from SE extracted 
sera were similar (data not shown). Taking swabs is 
less invasive than taking serum, which makes it more 
acceptable to populations, but is also safer and easier 
for sampling and testing. Since SE extraction does not 
require the use of a centrifuge, we tried to combine 
the RT-RPA with SE extraction of swabs to simplify our 
mobile laboratory procedure.
During the analysis of the results, we noted that the 
widely used A-PCR was less sensitive than the W-PCR. 
This lower Se was also described by other teams in 
Guinea and Sierra Leone [14,15]. A rapid detection test 
(ReEBOAg, Corgenix, Denver, US) was recently scored 
against the A-PCR with a Se of 91.8% and Sp of 84.6% 
and approved by the WHO for emergency use. Another 
recently described rapid detection test also scored a 
Se of 100% and a Sp of 96.6% against the A-PCR and 
was rated as a rule-out screening test by the authors 
because it would include all positives but would miss 
out on excluding all true negatives, therefore requiring 
a confirmatory test [15]. Our data confirm their interpre-
tation that the performance of these tests was under-
estimated when using the A-PCR as reference test.
Our data show that the combination of SE and RT-RPA is 
superior to the above rule-out tests as all true positive 
and negative post-mortem oral swabs are detected. Our 
previous work has shown that magnetic bead extrac-
tion is preferable to centrifuge-based extraction under 
field conditions as it obviates the need for a high-speed 
centrifuge (unpublished data). We therefore tested the 
novel magnetic bead-based SE extraction with its 15 
min protocol. The materials for both SE extraction and 
RT-RPA are stable at ambient temperature (30–35 °C) 
for up to three months and this cold chain-independent 
combination proved to be well suited for field diagnos-
tics. It scored very satisfactory results in swab extracts 
(Table 3, rows 13–14), indicating that the RT-RPA does 
not need a confirmatory test and can be used on site to 
correctly include positives and exclude negatives.
The prevalence of EBOV in the 928 swabs tested was 
12.9%. The day of death after onset of disease peaked 
at day 6 (range: 2–14 days) in the group of 67 swab-
positive deceased for whom disease symptoms were 
recorded. For the ongoing EBOV outbreak in West 
Africa, the mean day of symptom onset is 11 days after 
infection and sera should ideally be collected during 
the acute phase of illness, within the first 10 days of 
the disease [2]. We show here that the same is true for 
swabs, which could simplify diagnostics tremendously. 
In 53 positive cases, symptoms were not recorded, 
which was mainly due to a lack of information in the 
records of the Safe and Dignified Burial teams that did 
the sampling.
When new EVD foci erupted in previously not affected 
western parts of Conakry in April 2015, the mobile 
laboratory was deployed to Matoto to support teams 
in charge of safe and dignified burials. Since it had 
been decided that all deceased should be tested, 
these teams collected swab samples from deceased 
of five neighbourhoods of Conakry (Matoto, Ratoma, 
Dixinn, Matam and Kaloum) and up to 50 samples had 
to be tested per day. The emergency response results 
were provided every 30 to 60 min to the field inves-
tigators and physicians. The rapidity and mobility of 
the RT-RPA method in the DiaS, in comparison with the 
average 3 to 4 h turnover with regular real-time RT-PCR, 
was appreciated by burial teams, health authorities, 
response teams and communities, as it allowed rapid 
clearance for normal burials deceased persons who 
were confirmed negative. The results also encourage 
the use of swabs from patients at ETCs. In that context, 
it would still be necessary to determine if swab sam-
ples can replace sera samples.
The deployment demonstrated that the mobile labo-
ratory using glovebox, DiaS, SE and RT-RPA is a very 
good solution for decentralised biosafe diagnosis of 
EBOV, resulting in direct impact on community engage-
ment for disease control. Moreover, this small mobile 
laboratory run by local teams is a sustainable contribu-
tion to future outbreak control.
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